Skip to content
People

Perry Nisen

Chief Executive Officer at Quanta Therapeutics.

Earliest Form D on file: Jun 2026

Filed Jun 24, 2026Amendment

Quanta Therapeutics

Oral KRAS G12D and G12V inhibitors for cancer

Biotech, South San Francisco CA

Signed as Chief Executive Officer

$76.2M

sold of $89.1M offered

Form D

LinkedIn

Reported on an amendment to an earlier filing.

Network

At Quanta Therapeutics

6 people